title: Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
abstract: OBJECTIVE
  To assess if the percentage of cancer in prostate needle biopsies provides independent prognostic information for predicting pathological stage and/or biochemical relapse after radical prostatectomy.
  
  
  METHODS
  One hundred and forty prostate cancer patients who underwent radical prostatectomy were evaluated. Preoperative parameters analyzed were patient age, PSA, clinical stage, and the information obtained from sextant biopsies (Gleason score, maximum percentage of cancer in a core, percentage of tissue with cancer in all biopsies and the number of cores positive for cancer). Univariate and multivariate analyses (logistic regression) for the dependent variables (prostate cancer, organ-confined and biochemical relapse) were performed.
  
  
  RESULTS
  The tumor was organ-confined in 73.6% of patients. In those patients studied for disease progression (n = 126), no biochemical recurrence was observed in 76.2%. In the multivariate analysis for organ-confined disease, the total percentage of biopsy tissue with cancer, the preoperative PSA level, the Gleason score and the clinical stage were the most accurate predictive factors of pathological stage. The multivariate analysis for the study of biochemical failure indicated that only the total percentage of biopsy tissue with cancer, the preoperative PSA level and the Gleason score were independent predictive factors. According to the logistic regression analysis for disease recurrence, 3 risk groups could be identified: low risk (less than 10% probability of disease progression), intermediate risk (30%) and high risk (more than 70%).
  
  
  CONCLUSIONS
  The percentage of cancer in prostate biopsy provides independent prognostic information for predicting pathological stage and the risk of biochemical failure after radical prostatectomy.
authors.affiliation: Department of Urology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Villamón-Fort
authors.forename: José M
authors.initials: JM
authors.lastname: Martínez-Jabaloyas
authors.forename: Pilar
authors.initials: P
authors.lastname: Soriano-Sarriá
authors.forename: David
authors.initials: D
authors.lastname: Ramos-Soler
authors.forename: Francisco
authors.initials: F
authors.lastname: Pastor-Hernández
authors.forename: Manuel
authors.initials: M
authors.lastname: Gil-Salom
mesh_terms: D000368:Aged; D015415:Biomarkers; D001707:Biopsy, Needle; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies
chemical_list: D015415:Biomarkers; D017430:Prostate-Specific Antigen